Food and Drug Administration (FDA) has received reports of people experiencing stomach paralysis after taking certain GLP-1 Receptor Agonist (RA) drugs, like Ozempic, Wegovy, and Rybelsus
In SURPASS-CVOT, tirzepatide was non-inferior to dulaglutide in the prevention of major cardiovascular events
Two compounds to source, two batches to verify
A research-first review of post-cycle recovery concepts, evidence limits, and risk-aware planning for peptide-focused protocols
The semaglutide to tirzepatide conversion experience offers useful parallels, since that transition also introduces GIP agonism
Can I get same-day appointments for ADHD and anxiety treatment in Austin